The autonomic nervous system, the renin-angiotensin-aldosterone system, and the natriuretic peptide system represent critical regulatory pathways in heart failure and as such have been the major targets of pharmacological development. The introduction and approval of angiotensin receptor neprilysin inhibitors (ARNi) have broadened the available drug treatments of patients with chronic heart failure with reduced ejection fraction. Neprilysin catalyses the degradation of a number of vasodilator peptides, including the natriuretic peptides, bradykinin, substance P, and adrenomedullin, as well as vasoconstrictor peptides, including endothelin-1 and angiotensin I and II. We review the multiple, potentially competing, substrates for neprilysin inhibition, and the resultant composite clinical effects of ARNi therapy. A mechanistic understanding of this novel therapeutic class may provide important insights into the expected on-target and off-target effects when this agent is more widely prescribed.
Introduction
Heart failure (HF) is a complex clinical syndrome characterized by abnormalities in cardiac structure and function, dynamic remodelling, and perturbations of the neurohormonal axis. 1 Neurohormonal regulatory mechanisms contribute to and modulate key pathways leading to HF, acting through three main systems: the autonomic nervous system (ANS), the renin-angiotensin-aldosterone system (RAAS), and the natriuretic peptide system (NPS). 2 Different pharmacological approaches have been used to treat the neuroendocrine dysregulation in HF, including angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptors blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), and beta-blockers (BBs). 3 Recently, the concept of neuro-modulation, rather than neuro-inhibition, has been successfully tested with the angiotensin receptor neprilysin inhibitor (ARNi) class, representing a potential shift in the treatment of HF from partial neurohormonal system inhibition to an integrated composite neurohormonal system modulation. 4 continued characterization and profiling of established and emerging biomarkers, together with molecular substrates of neprilysin (NEP), may inform ongoing therapeutic development efforts and provide information on prognosis and risk stratification. Herein, we review the multiple, potentially competing, substrates for NEP inhibition, and the resultant composite clinical effects of ARNi therapy. 6 
Neurohormonal pathways in heart failure
The ANS regulates cardiac, vascular, and visceral functions through the actions of the sympathetic nervous system (SNS) and the parasympathetic nervous system, which in turn contribute to overall excitatory or inhibitory inputs on target organs. 7, 8 The RAAS axis is one of the most critical homeostatic systems in normal physiology. Excess RAAS activity may contribute to pathological clinical alterations in HF, such as volume retention, peripheral vasoconstriction, and myocyte hypertrophy. RAAS activation potentiates angiotensin II (Ang II) production, which facilitates myocyte growth and stimulates norepinephrine release. 9 The NPS is a system composed of three structurally related hormones/paracrine factors: atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). ANP and BNP are secreted from the cardiac atria and ventricles, respectively. CNP, produced in brain, chondrocytes and endothelial cells, activates a related cyclase, catalysing the synthesis of cyclic guanosine monophosphate (cGMP). All natriuretic peptides (NPs) are synthesized as pre-prohormones and have varying effects on endocrine function, cardiac and kidney homeostasis, and blood volume control.
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Conventional neurohormonal inhibition in heart failure
Traditional drug development in HF has centred on the step-wise attenuation of SNS and RAAS, as secondary pathways responsible for long-term ventricular remodelling 12 via the inhibition of the SNS with BBs and of the RAAS axis with ACEi/ARBs and MRAs. Neuromodulation with ARNi simultaneously influences the RAAS and NPS pathways, and thus represents a successful and innovative approach in HF drug development. 13 -15 A novel approach in heart failure: neurohormonal modulation NEP, an endothelial cell surface zinc metallopeptidase, is widely expressed in endothelial cells, smooth muscle cells, cardiac myocytes, renal epithelial cells, and fibroblasts. It is found in the lung, gut, adrenal glands, brain, and heart. NEP catalyses the degradation of vasodilator peptides, including ANP, BNP, CNP, bradykinin (BK), substance P (SP), and adrenomedullin (ADM) to varying degrees, as well as vasoconstrictor peptides, including endothelin 1 (ET-1) and Ang II. What determines the relative specificity and affinity of NEP to this broad spectrum of substrates? The catalytic site of NEP, like other proteases, has a specific size, shape, and unique distribution of charges that aid in the binding of the substrate to the catalytic site within the enzyme. The binding site within NEP does not vary, but it does have characteristics that may be optimal for one substrate and sub-optimal for another. As such, NEP displays varying relative affinities among different substrates: its highest affinity is for ANP, CNP, and Ang I and II, while its lowest affinity is for BNP, ET-1, and BK ( Figure 1) . 16 Unfortunately, there are limited data exploring the effects of NEP inhibition with endogenous substrates (as opposed to small synthetic peptides) at various concentrations, which may represent an important area of future mechanistic study. Indeed, the net effect of NEP inhibition on vascular tone will depend on whether the predominant substrates degraded are vasodilators or vasoconstrictors. Consequently, a benefit obtained from enhancing the NPS may be offset by increased Ang II. Bayés-Genís and colleagues recently characterized circulating NEP levels in a large consecutive cohort of patients with chronic HF followed for a mean of 4 20 could not confirm an association between NEP levels and cardiovascular mortality or hospitalization for HF, in contrast to HFrEF. Soluble NEP may provide independent information beyond available biomarkers commonly used for HF risk stratification, and supports a potential strategy of therapeutic NEP inhibition in HFrEF; 21 further data are required to clarify the prognostic impact of NEP and the value of its therapeutic modulation in HFpEF.
Neprilysin inhibition via sacubitril/valsartan (LCZ696)
For decades, NEP has been an important biological target. Initially, NEP inhibition as monotherapy was tested. Although candoxatril showed promising preliminary effects on haemodynamic parameters, ecadotril led to higher mortality, with no evidence of clinical efficacy compared with placebo in HF patients. 22, 23 Consequently, the development of NEP inhibition monotherapy for HF was discontinued. Given the mixed substrates of NEP, emerging data revealed upregulation and unopposed activity of RAAS with the inhibition of NEP alone. These findings inspired the development of a drug combining NEP inhibition and ACEi: the vasopeptidase inhibitors. Several vasopeptidase inhibitors have been tested, including omapatrilat, fasidotril, sampatrilat, and mixanpril. Omapatrilat reduced the risk of cardiovascular death and the readmission for HF by approximately 10% when compared with enalapril. However, since BK is a target of NEP, the combined increase in BK levels with both NEP inhibition and ACEi led to an increase in clinically relevant episodes of angioedema, 24 especially in African Americans. These treatment-emergent adverse events with the combined inhibition of NEP and ACE slowed the enthusiasm for the further development of this therapeutic class.
Sacubitril/valsartan (LCZ696) is a first-in-class approved ARNi, that simultaneously provides NEP inhibition and blockade of the Ang II type I receptor. In the landmark PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial, sacubitril/valsartan reduced the risk of death from cardiovascular causes by 20% [13.3% vs. 16 .5%; hazard ratio (HR) 0.80; P < 0.001] and the risk of hospitalization for HF by 21% (12.8% vs. 15.6%; HR 0.79; P < 0.001) compared with enalapril in patients with HFrEF. 25 The relative efficacy of sacubitril/valsartan vs. enalapril appears to be maintained even in patients that required dose reduction during the course of the trial. 26 The innovative concept underlying NEP inhibition in HF represents a shift from neurohormonal inhibition to neurohormonal modulation. 5, 27 Sacubitril/valsartan results in vasodilation, reduction in blood volume, and increased sodium and water excretion via the kidneys, by reducing aldosterone production via its ARB-based effects. Sacubitril/valsartan lowers blood pressure, mainly due to blood volume reduction and natriuresis. Indeed, sacubitril/valsartan promotes neurohormonal balance, leading to early relief of HF signs and symptoms, and long-term improvement in left ventricular remodelling. These benefits at the neurohormonal level translate into reductions in the major modes of death in HFrEF, including sudden cardiac death and worsening HF. 28 Regarding the off-target risks and adverse effect profile of sacubitril/valsartan in the PARADIGM-HF trial, sacubitril/valsartan-treated patients had a higher proportion of hypotension; however, the total number of patients discontinuing the study drug was higher in the enalapril group. Other adverse effects reported in the trial were renal impairment, hyperkalaemia, and cough, but to a lower extent compared with the enalapril group. Sacubitril/valsartan has also been tested in a phase 2 trial in HFpEF, the PARAMOUNT (Prospective comparison of ARNi with ARB on Management of Heart Failure with Preserved Ejection Fraction) trial. 29 In 301 patients with ejection fraction > 45% and N-terminal proBNP (NT-proBNP) > 400 pg/mL, the reduction in NT-proBNP at 12 weeks was greater in the sacubitril/valsartan group compared with the valsartan group. Nevertheless, this difference was no longer significant at 36 weeks. The trial was not designed to determine clinical effects on outcomes, but it has provided the rationale for an ongoing large definitive phase III trial in HFpEF [Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF), ClinicalTrials.gov Identifier: NCT01920711]. Sacubitril/valsartan has been approved for use in patients with chronic HFrEF, has garnered strong support from US and European guidelines, 3, 30 and its clinical uptake in practice is expected to increase with time. In this review, we summarize the predominant relative vasomotor effects (vasoconstriction vs. vasodilation, Figure 2 ) of major NEP substrates, with a focus on their physiological effects, distribution, and association with prognosis in HF ( 
Neprilysin substrates promoting peripheral vasodilation
NEP substrates that promote peripheral vasodilation include NPs, BK, SP, and ADM. To date, all major therapies in the contemporary HF drug armamentarium lower systemic blood pressures. Despite application of stringent enrolment criteria and run-in periods, symptomatic hypotension was common occurring in 14% of patients randomized to sacubitril/valsartan in PARADIGM-HF. 25 Similarly, symptomatic hypotension was the most common adverse event reported with sacubitril/valsartan in trial, with a frequency of 19%. 29 A deeper mechanistic understanding of the therapeutic effects of NEP inhibition on the following vasodilatory peptides may provide insights into strategies to limit treatment-related hypotension, especially in high-risk vulnerable groups.
Natriuretic peptides: ANP, BNP, and CNP
The NPS includes three different NPs: ANP, BNP, and CNP. ANP is derived from pre-proANP, a 151 amino acid precursor, and is primarily expressed and stored in the atria, although lower concentrations can be found in the ventricles and in the kidneys. Atrial wall stress stimulates ANP secretion. Human BNP is similarly synthesized as a prehormone, pre-proBNP, a 134 amino acid peptide and cleaved into proBNP, which is 108 amino acids in length. ProBNP is subsequently cleaved into the biologically active 32 amino acid BNP, plus the 76 amino acid NT-proBNP. Although low levels of BNP are found in the atria, a greater concentration of BNP is stored in the ventricles, and it is released in response to cardiac stress, such as volume overload. CNP is the most expressed NP in the brain, but it is also produced in chondrocytes and endothelial cells. After a vascular insult or endothelial injury, CNP neo-intimal expression increases. 31 NPs and their receptors mediate different physiological effects ranging from blood pressure control to cardiac hypertrophy 
The table is organized into substrates of neprilysin that are vasodilators (green) and vasoconstrictors (orange). ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide; CNP, C-type natriuretic peptide; NO, nitric oxide. and remodelling inhibition. In the kidney, ANP increases glomerular filtration rate, decreases sodium and water reabsorption, and reduces renin secretion. In the heart, both ANP and BNP inhibit cardiomyocyte hypertrophy induced by Ang II and ET-1, and attenuate norepinephrine-induced growth of cardiac myocytes and fibroblasts. CNP acts as a vasodilatory peptide and participates in the paracrine action of other vasorelaxant mediators, such as nitric oxide (NO) and prostacyclin. 32, 33 CNP also stimulates long bone growth. The three NPs are inactivated by receptor-mediated internalization and lysosomal degradation, followed by enzymatic neutral endopeptidase or NEP degradation. It has been recently shown that NEP inhibition modestly increases BNP level compared to enalapril. 34 Altered processing of BNP occurs in HF, based on the evidence that most of the BNP detected by clinical BNP assays is a different degradation product of BNP and of the less biologically active prohormone, proBNP1-108 and BNP1-32. 35 to reduce NT-proBNP (reflecting reduced cardiac wall stress) early after treatment initiation and durably throughout trial follow-up. A greater number of sacubitril/valsartan-treated patients (compared with those receiving enalapril) achieved NT-proBNP levels ≤1000 pg/mL, which was, in turn, associated with improved clinical outcomes. 37 The contrasting effects of sacubitril/valsartan on these two NPs represent an important finding because the levels of the two peptides are typically concordant in chronic HF. 38 Elevation of BNP and concurrent decline in NT-proBNP are commonly attributed to delayed BNP metabolism and decreased cardiac release of B-type peptides; however, it has been documented that ARNi may promote peptide glycosylation, not only impeding cleavage of proBNP into BNP and NT-proBNP, but also rendering NT-proBNP invisible to current immunoassays. 39 Further research is required to understand whether levels of BNP can be used to track compliance on therapy, while levels of NT-proBNP may be used to track clinical response over time to ARNi therapy.
Bradykinin
BK is a peptide made up of nine amino acids that increases vascular permeability and acts as a potent vasodilator through stimulation of specific endothelial B 2 receptors. In humans, BK is broken down by three kinases: ACE, aminopeptidase P (APP), and carboxypeptidase N (CPN). 41 ACEi stimulate the endothelial release of NO and prostacyclin by a BK-mediated mechanism, thus increasing endothelium-dependent vasodilation. ACE inhibition both reduces levels of Ang II and increases BK, which leads to vasodilation and hypotension. 42, 43 BK has a potentially beneficial role in HF, but may increase risk of angioedema. 44 High levels of BK increase vascular permeability of the post-capillary venules and allow for plasma extravasation into the submucosal tissue, leading to angioedema. Sacubitril/valsartan was designed to have a reduced risk for angioedema because it inhibits only one of the enzymes responsible for BK breakdown. Initial experience with omapatrilat, which inhibits both NEP and ACE (and probably also APP), resulted in an unacceptable risk of angioedema, especially in African American patients. 45 It should be noted, however, that 6532 of 8442 patients enrolled in PARADIGM-HF were previously treated with an ACEi, and that all patients were exposed to enalapril during the single-blind run-in period. 25 As a matter of fact, this may have introduced selection bias and led to an under-representation of angioedema in the trial, because >50% of cases of ACEi-associated angioedema occur within the first week of treatment initiation. 46 In addition, the incidence of angioedema in the PARADIGM-HF trial may be underestimated given the low proportion of African Americans enrolled in the study, a group at increased risk of ACEi-and vasopeptidase inhibitor-associated angioedema. 25, 47 Substance P SP is an undecapeptide member of the tachykinin neuropeptide family, which acts as a neurotransmitter and as a neuromodulator. 48 SP is released from sensory nerve terminals in both the central and peripheral nervous systems. Although its levels are low in the myocardium, it can affect the heart due to its role in nociception, inflammation, plasma extravasation, platelet and leucocyte aggregation in post-capillary venules, and leucocyte chemotactic migration through vessel walls. 49 In the heart, SP-containing nerve fibres are located in the intrinsic ganglia of the myocardium and around coronary vessels. In addition, a small number of coronary endothelial cells contain SP. Of note, localization of SP-containing nerve fibres around the coronary arteries, as well as in coronary artery endothelial cells, may suggest that this neuropeptide is ideally placed to be released in response to changes in coronary arterial pressure or in situations of haemodynamic stress. SP can be considered as a potent vasodilator through NO release. 50 As with some other vasodilators, SP also has bronchoconstrictive properties via its effects on the non-adrenergic, non-cholinergic nervous system (branch of the vagal system). Overall, SP has two distinct effects in response to myocardial insult or overload. Short-term, SP vasodilatory effects appear to be protective by increasing myocardial perfusion, as demonstrated by ischaemia-reperfusion studies. On the other hand, long-term up-regulation of SP appears to be associated with inflammation, apoptosis, matrix metalloproteinase . activation, and alterations of extracellular matrix, which may collectively lead to adverse remodelling and worsening HF. 51 Most studies have been performed in normal hearts, thus the role of SP in pathological disease states requires better understanding. As a vasodilator substrate, SP could be responsible for blood pressure lowering as a side effect of sacubitril/valsartan. Reassuringly, in the case of sacubitril/valsartan, the long-term harmful accumulation of substance P may be attenuated as this peptide is broken down by the uninhibited ACE.
Adrenomedullin
Human ADM is a 52 amino acid peptide, which is produced from its precursor molecule preproadrenomedullin. Since the discovery that the ADM gene is expressed to a greater extent in endothelial cells than in the adrenal medulla, it has been recognized that this peptide should be considered as a secretory product of the vascular endothelium, together with NO and endothelin (ET). 52 In addition to vascular endothelium, evidence from immunocytochemistry and cell culture studies reveals that the ADM gene is expressed by very different cell types, in all tissues of the body, with the exception of the thyroid and thymus. ADM levels in the plasma and tissues are regulated by the proteolysis of NEP, the major enzyme of ADM degradation.
ADM has natriuretic, vasodilatory, and hypotensive effects that are mediated by the cyclic adenosine monophosphate (cAMP), NO, and renal prostaglandin systems. ADM has a large range of additional actions, from cellular growth and differentiation, through to modulating hormone secretion, to endocrine, renal, gastric, immunological, and antimicrobial effects. 53 Several recent studies have shown diagnostic and prognostic significance of ADM in patients with HF. 54 -56 ADM is elevated in HF proportional to the severity of the disease, as assessed by New York Heart Association (NYHA) class and the degree of left ventricular impairment. In the BACH (Biomarkers in Acute Heart Failure) trial, the independent utility of mid-regional proADM compared with traditional BNP in predicting short-term survival was demonstrated in patients with acute HF. 57 In anaesthetized dogs, NEP inhibition potentiates ADM-induced natriuresis and diuresis, causing a certain degree of hypotension as a side effect. 58 This potentiation occurs secondary to a decrease in tubular sodium reabsorption in association with renal vasodilation. In another sheep HF model, NEP inhibition potentiated the vasodilator response to intravenous ADM, while preserving natriuresis and diuresis. 59 Neprilysin substrates promoting peripheral vasoconstriction NEP substrates of peripheral vasoconstriction include ET, and mediators of the RAAS system, including Ang II.
circulation and vascular endothelium of multiple tissues. Circulating Ang II stimulates sodium and water reabsorption, increases fluid volume, causes systemic arteriolar vasoconstriction, and potentiates vascular resistance and cardiac afterload. 60 Ang II also stimulates SNS and reduces vagal activity. Indeed, there is substantial interplay between the RAAS and ANS pathways. The SNS stimulates the release of renin by the juxta-glomerular cells, and both Ang II and aldosterone potentiate norepinephrine release at the synaptic level, preventing its reuptake. 61 The SNS also influences regulation of salt handling, arterial blood pressure, and renal electrolyte shifts.
Endothelin
ET is a 21 amino acid peptide with powerful vasoconstrictor properties that has a long-term effect on vascular smooth muscle cell proliferation and phenotype. 62 ET is synthesized as a large preprohormone (big ET-1) that is cleaved to pro-ET, which is subsequently cleaved into ET-1, ET-2, and ET-3. ET-1 is the most potent vasoconstrictor present in the human vasculature. ETs are rapidly cleared from the circulation by the lungs, liver, and kidneys. ET-A receptors are located on vascular smooth muscle cells where they mediate vasoconstriction and cell proliferation. ET-B receptors are primarily found on vascular endothelial cells where they mediate vasodilation via release of endothelium-derived NO. Nonetheless, in humans the vasoconstrictor effects of ET-1 predominate, resulting in concentration-dependent contraction of systemic and pulmonary arteries, since elevated levels of ET-1 are mainly due to increased release from the lungs and myocardial cells. Several studies have demonstrated that HF is associated with high plasma levels of ET-1, which correlate closely with disease severity. 63 -66 Wei et al. 67 showed that circulating ET-1 levels were elevated in patients with NYHA class III-IV HF, but not in mild HF (NYHA class II). The prognostic role of ET-1 was further established by Pousset and colleagues. 68 In this small study, ET-1 was an independent predictor of long-term outcome in 120 patients with HF. Stangl et al. 69 further demonstrated that ET-1 may be useful as a marker of response to therapy. In this study, plasma ET-1 levels were decreased by vasodilator therapy in patients with chronic HF receiving treatment for acute decompensation. It is noteworthy that clinical trials failed to establish any benefit from the administration of ET receptor antagonists in patients with HFrEF (NYHA class II-IV). There was in fact some evidence of harm with ET receptor antagonists, including fluid retention and liver function test abnormalities. 70, 71 Another substrate of neprilysin inhibition: amyloidSerious concerns have been raised regarding the role of NEP in the development of Alzheimer's disease (AD). AD is a complex disease that develops over a long period, and is associated with the presence of amyloid beta (A ) plaques in the brain. There is evidence that NEP has protective activity against AD by degrading the A peptide. Inhibition of NEP in mice has resulted in a large increase in the levels of A and plaque-like deposits in the brain, which may lead to cognitive impairment. 72 74 may offer promise in reducing long-term neurovascular events. Furthermore, after 4.3 years of sacubitril/valsartan use in the PARADIGM-HF treatment group, there was observed no increase in incidence of AD or dementia-related adverse events compared to the control group, although neurocognitive testing was not independently adjudicated or routinely performed. 25 [Correction added on 07 April 2017, after first online publication: "no" was inserted to correct the previous sentence]. Similarly, in the 36-week PARAMOUNT study, no excess in neurological adverse effects was seen. 29 However, these trials were not prospectively designed to specifically evaluate the effects of sacubitril/valsartan on neurocognitive function, AD, or other forms of dementia. Recently, Cannon et al. analysed the dementia-related adverse effects in the PARADIGM-HF trial and placed these findings in the context of other HFrEF trials finding no evidence that sacubitril/valsartan, compared with enalapril, increased dementia-related adverse events. 75, 76 Given the ageing population and that sacubitril/valsartan appears to have consistent clinical effects across the age spectrum, 77 careful attention to potential off-target neurological effects in elderly patients exposed to ARNi therapy is required. In response to these concerns, a multicentre, randomized, double-blind, active-controlled study to evaluate the effects of sacubitril/valsartan compared to valsartan on cognitive function in patients with HFpEF has been recently designed [Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Heart Failure and Preserved Ejection Fraction (PERSPECTIVE), ClinicalTrials.gov Identifier: NCT02884206] and is poised to begin active enrolment. As the clinical uptake of ARNi therapy improves globally, registry-based 'real-world' experiences are required for more broad-scale surveillance of these rare, but potentially impactful neurological adverse effects. Indeed, regional pharmacovigilance programmes may be integral to the ongoing evaluation of the safety of sacubitril/valsartan, especially in high-risk elderly populations.
Conclusions
To date, the therapeutic approach in HFrEF has been based on RAAS and SNS inhibition. The recently approved sacubitril/valsartan (LCZ696) has been shown to improve morbidity and mortality in HFrEF; however, the exact mechanisms contributing to its efficacy and safety profile have not been entirely clarified. NEP is responsible for degrading several substrates, with different, if not opposing, biological actions. Each NEP substrate, beyond the well-recognized NP axis, may provide incremental information into better understanding the therapeutic actions of this novel class of agents. Given the ageing HF demographic and that the ARNi class is expected to be prescribed more broadly, careful and dedicated assessment of potential off-target effects of this novel class is required given its myriad of biological effects. Longer-term follow-up of unselected patients exposed to ARNi therapy is required to inform its expected 'real-world' efficacy and safety. It is also important to recognize that, although this review highlights pathways of secondary neurohormonal vasodilation and vasoconstriction in the peripheral circulation, better definition of mechanisms and targets intrinsic to the heart (including at the level of mitochondria, capillaries, interstitium, myocytes, etc.) will be important for future drug development.
